{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:53:25Z","timestamp":1787162005625,"version":"build-2736575974"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,6,23]],"date-time":"2006-06-23T00:00:00Z","timestamp":1151020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:p>\n                    <jats:bold>Abstract:\u2002<\/jats:bold>\n                    CD178 (Fas\/APO\u20101 ligand) and CD137 ligand (CD137L) have previously been described in sera of patients with various malignancies and play an important role in the pathogenesis of various diseases. Recently, we demonstrated that low levels of soluble (s) CD137L and high levels of sCD178 correlate significantly with a long progression free survival in patients with myelodysplastic syndrome (MDS). In this study, we correlated sCD137L and sCD178 levels in sera of 42 samples of patients with acute myeloid leukemia (AML) and 46 samples of patients with non\u2010Hodgkin's lymphoma (NHL) with stages, subtypes, and the clinical course of the diseases and determined cut\u2010off values with maximum probability for significant differentiation between cases with higher\/lower probability for progress free survival. In contrast to patients with MDS, surprisingly no correlation between sCD178 levels and different subtypes and stages or with prognosis in AML or NHL were observed. Regarding sCD137L, NHL\u2010patients displayed lower levels compared with AML. Statistically significant higher median levels of sCD137L are present in patients with undifferentiated AML (M1\/M2, 1470\u2003pg\/mL), poor cytogenetic risk (288\u2003pg\/mL) and higher levels of BM\u2010blasts (186\u2003pg\/mL) compared with patients with monocytoid AML (M4\/M5, 89\u2003pg\/mL), intermediate cytogenetic risk (59\u2003pg\/mL) and lower levels of BM\u2010blasts (14\u2003pg\/mL) respectively. Furthermore, in AML patients sCD137L levels correlate significantly with the probabilities to achieve complete remission (CR), stay in CR or with progress of the disease. Taken together, our data demonstrate that sCD137L can be used as a prognostic factor not only in MDS but also in AML.\n                  <\/jats:p>","DOI":"10.1111\/j.1600-0609.2006.00679.x","type":"journal-article","created":{"date-parts":[[2006,6,23]],"date-time":"2006-06-23T08:34:45Z","timestamp":1151051685000},"page":"91-101","source":"Crossref","is-referenced-by-count":20,"title":["Serum levels of sCD137 (4\u20101BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non\u2010Hodgkin's lymphoma"],"prefix":"10.1111","volume":"77","author":[{"given":"N.","family":"Hentschel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Krusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. A.","family":"Kiener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. J.","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. R.","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. M.","family":"Schmetzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,6,23]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"1556","article-title":"Retrospective analysis of 304 cases of malignant lymphomas in pathology: study and practise of the WHO classification on lymphoid naoplasms","volume":"83","author":"Yin HF","year":"2003","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-003-1157-6"},{"key":"e_1_2_6_4_2","first-page":"63","article-title":"Proliferation in non\u2010Hodgkin's lymphomas and its prognostik value related to staging parameters","volume":"26","author":"Lorand\u2010Metze I","year":"2004","journal-title":"Cell Oncol"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13868-8"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1199"},{"key":"e_1_2_6_7_2","first-page":"877","article-title":"Consensus protocol for the flow cytimetric immunophenotyping of hematopoietic malignancies","volume":"10","author":"Rothe G","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_6_8_2","first-page":"1087","article-title":"Efficacy and safety of gemtuzumab ozogamicin in patients with CD33\u2010positive acute myeloid leukemiain fist relapse","volume":"22","author":"Sievers EL","year":"2004","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.005"},{"key":"e_1_2_6_10_2","first-page":"487","article-title":"The TNF and TNF receptor superfamilies: integrating mammalian biology","volume":"104","author":"Locksley RM","year":"2001","journal-title":"Cell Press"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.5.2903"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.7.4059"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11574"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.3.985"},{"key":"e_1_2_6_15_2","first-page":"369","article-title":"Fas ligand expression on nodal non\u2010Hodgkin's lymphoma","volume":"11","author":"Mullauer L","year":"1998","journal-title":"Mod Pathol"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4797"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.5.3174"},{"key":"e_1_2_6_18_2","first-page":"275","article-title":"Biochemical and immunological characteristics of 4\u20101BB (CD137) receptor and ligand and potential applications in cancer therapy","volume":"47","author":"Sica G","year":"1999","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700670"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1385\/IR:29:1-3:197"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2787530"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-005-0680-7"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.3.1165"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.00933.x"},{"issue":"1","key":"e_1_2_6_25_2","first-page":"202","article-title":"Fas\/CD178 system could be one of the mediators of excessive apoptosis in myelodysplastic syndromes","volume":"90","author":"Mativi BY","year":"1997","journal-title":"Blood"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401233"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1594"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03382.x"},{"key":"e_1_2_6_29_2","first-page":"76","article-title":"Membrane\u2010bound Fas (Apo\u20101\/CD95) ligand on leukamic cells: a mechanism of tumor immune escape in leukemia patients","volume":"117","author":"Buzyn A","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/emm.2004.2"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI7014"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1997.d01-901.x"},{"key":"e_1_2_6_33_2","first-page":"398","article-title":"CD27 in B\u2010cell chronic lymphocytic leukemia. Cellular expression, serum release and correlation with other soluble molecules belonging to nerve growth factor receptors (NGFr) superfamily","volume":"83","author":"Molica S","year":"1998","journal-title":"Haematologica"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.8.1205"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0198-031"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1006\/excr.2001.5346"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001602372"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(20000115)19:1<113::AID-SIM245>3.0.CO;2-O"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.1999.00851.x"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.9.3161"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2006.00679.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2006.00679.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T22:10:53Z","timestamp":1696975853000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2006.00679.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,23]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1111\/j.1600-0609.2006.00679.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2006.00679.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,23]]}}}